Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.
On May 9, 2025, Dr. Reddy’s Laboratories announced the release of its audited financial results for the fourth quarter and the financial year ending March 31, 2025. This announcement, made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, provides stakeholders with insights into the company’s financial performance over the past year. The release of these results is significant for investors and market analysts as it offers a detailed view of the company’s financial health and operational performance.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a pharmaceutical company based in Hyderabad, India. It is involved in the manufacturing and marketing of a wide range of pharmaceutical products and services, with a focus on generic medications and active pharmaceutical ingredients. The company is listed on multiple stock exchanges including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.
Average Trading Volume: 2,186,475
Technical Sentiment Signal: Hold
Current Market Cap: $11.39B
Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.